A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
The sale of remaining rights to Allogene ends acrimony between the two companies.
Keyvibe-010 fails, but not for the reason you might have expected.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
But the group’s attempt to join Janux at the high altar of masking technology falls flat.